Al-Hashimi Nawal Haider, Al-Hindawi Mohammed S, Mohsen Ali M, Al-Gebori Abdulnasser M
Applied Sciences Department, University of Technology-Iraq, 10001 Baghdad, Iraq.
Front Biosci (Schol Ed). 2024 Apr 30;16(2):9. doi: 10.31083/j.fbs1602009.
Coronavirus disease 19 (COVID-19), an infectious disease resulting from a virus known as severe acute respiratory syndrome coronavirus 2 (SARS-COV-2), was discovered in China in 2019 and causes several mild to moderate respiratory conditions. This study aimed to reveal the changes in serum interleukin-10 (IL-10) and other parameters in Iraqi COVID-19 patients compared with healthy controls by studying the effects of enoxaparin and evaluating the potential of IL-10 as a disease activity marker.
This was a case-control study that included 180 samples: 90 patients hospitalized with COVID-19 from November 2022 to 20 April 2023 (40 patients had never used enoxaparin, whereas 50 patients had taken enoxaparin) and 90 healthy, age- and sex-matched control. There were 44 female patients and 46 male patients. The mean age of the patients and controls was 53.8 years 50.8 years, respectively. The sandwich enzyme-linked immunosorbent assay (ELISA) method was used to measure IL-10 levels, while other parameters were assessed using the colorimetric method.
The results of the study indicated highly significant changes between the patients and healthy controls in IL-10, D-dimer, and C-reactive protein (CRP) levels, as well as liver and renal functions. These findings elucidated a significant change between enoxaparin patients and non-enoxaparin patients in IL-10, D-dimer, and CRP levels. However, the liver and renal functions were not significantly altered. The Spearman's rank correlation test investigated the relationship between serum IL-10 and CRP.
The results displayed a strong positive relationship between IL-10 and CRP. There were no significant differences between the other analyzed parameters; consequently, the patients had higher concentrations of IL-10, D-dimer, and some other parameters than the healthy controls. Additionally, IL-10 may be used as a marker of disease activity. Enoxaparin will likely help control IL-10 and D-dimer concentrations in patients since IL-10 levels decreased in patients treated with enoxaparin.
2019年在中国发现了新型冠状病毒肺炎（COVID-19），这是一种由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起的传染病，可导致多种轻度至中度呼吸道疾病。本研究旨在通过研究依诺肝素的作用并评估白细胞介素-10（IL-10）作为疾病活动标志物的潜力，揭示伊拉克COVID-19患者与健康对照相比血清IL-10和其他参数的变化。
这是一项病例对照研究，包括180个样本：2022年11月至2023年4月期间住院的90例COVID-19患者（40例从未使用过依诺肝素，50例使用过依诺肝素）和90例年龄和性别匹配的健康对照。其中有44例女性患者和46例男性患者。患者和对照的平均年龄分别为53.8岁和50.8岁。采用夹心酶联免疫吸附测定（ELISA）法测量IL-10水平，而其他参数采用比色法评估。
研究结果表明，患者与健康对照在IL-10、D-二聚体、C反应蛋白（CRP）水平以及肝肾功能方面存在高度显著变化。这些发现阐明了使用依诺肝素的患者与未使用依诺肝素的患者在IL-10、D-二聚体和CRP水平上的显著差异。然而，肝肾功能没有明显改变。采用Spearman等级相关检验研究血清IL-10与CRP之间的关系。
结果显示IL-10与CRP之间存在强正相关。其他分析参数之间无显著差异；因此，患者的IL-10、D-二聚体和其他一些参数浓度高于健康对照。此外，IL-10可作为疾病活动的标志物。依诺肝素可能有助于控制患者体内IL-10和D-二聚体的浓度，因为使用依诺肝素治疗的患者IL-10水平有所下降。
